 |
|
|
|
|
|
|
|
 |
Results for 'Roche Deals' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Roche Holding AG -Deals & Alliances Report
|
February 2008 |
£300 |
100 % |
Partneringdesk deals and alliances in cardiovascular diseases
|
April 2006 |
£1250 |
41 % |
Partneringdesk deals and alliances in metabolic diseases
|
April 2006 |
£1250 |
39.5 % |
Partneringdesk deals and alliances in genitourinary and gynecological diseases
|
April 2006 |
£1250 |
39.5 % |
Partneringdesk deals and alliances in infectious diseases
|
April 2006 |
£1250 |
39.5 % |
Partneringdesk deals and alliances in musculoskeletal diseases
|
April 2006 |
£1250 |
39 % |
Partneringdesk deals and alliances in blood and lymphatic diseases
|
April 2006 |
£1250 |
39 % |
Partneringdesk deals and alliances in autoimmune & inflammatory diseases
|
April 2006 |
£1250 |
38.5 % |
Roche Partnering Guide 2008
|
July 2021 |
£195 |
35 % |
Risk-Sharing in the Pharmaceutical Industry
The Case of Out-Licensing
|
January 2006 |
£50 |
30 % |
Pre-clinical Stage Partnering Agreements in Biopharma
|
October 2010 |
£1195 |
24.85 % |
Pharmaceutical Licensing Strategies
Best practices in deal-making, valuations and strategic management
|
June 2006 |
£1495 |
24.15 % |
Roche Holdings Ltd -Detailed Product Pipeline
|
February 2008 |
£375 |
24 % |
Switzerland Pharmaceuticals and Healthcare Report Q4 2008
|
October 2008 |
£425 |
24 % |
Effective Licensing & Commercialisation of Drug Delivery Systems
2006
|
July 2006 |
£2500 |
23.8 % |
Distribution Agreements in Biopharma
|
April 2001 |
£1195 |
23.8 % |
Discovery Stage Partnering Agreements in Biopharma
|
September 2001 |
£1195 |
23.8 % |
Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
|
November 2011 |
£1195 |
23.8 % |
Partnering with Biopharma
The definitive guide to bigpharma partnering interests, contacts & agreements
|
July 2001 |
£1495 |
23.8 % |
F. Hoffmann-La Roche Ltd.
Strategic Analysis Profile
|
February 2008 |
£515 |
23.45 % |
Late Stage Deals
Strategy, Structure and Payment Terms
|
August 2004 |
£950 |
23.45 % |
Partneringreview 2006
|
February 2006 |
£2195 |
23 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
23 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
22.5 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
22.5 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
22.5 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
22.5 % |
Manufacturing & Supply Agreements in Biopharma
|
April 2001 |
£1195 |
22.4 % |
Clinical Stage Partnering Agreements in Biopharma
|
June 2001 |
£1195 |
22.05 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
22 % |
Pharmaceutical Strategic Alliances
Maximizing returns from collaborative development and commercialization
|
September 2006 |
£1495 |
21.35 % |
Stakeholder Insight: Heart Failure
Pumping Up Therapy Will Prevent Failure
|
June 2005 |
£8000 |
21.35 % |
Co-promotion & Co-marketing Agreements in Biopharma
|
January 2001 |
£1195 |
20.65 % |
PharmaVitae 2005: Roche Global Analysis
|
June 2005 |
£2005 |
20.3 % |
Bigpharma Agreements Handbook
Partnering Agreements
|
September 2001 |
£2195 |
19.6 % |
Bigpharma Partnering Agreements
|
March 2001 |
£1195 |
19.6 % |
PharmaVitae 2005: Roche Global and US Analysis
|
June 2005 |
£3000 |
19.6 % |
Merger & Acquisition Agreements in Biopharma
|
February 2001 |
£1195 |
19.6 % |
Market Development in Anti-virals:What is Next?
What is Next?
|
August 2004 |
£420 |
19.5 % |
Effectively Selling Medical Devices in Europe
|
June 2007 |
£295 |
17.5 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£7600 |
16.8 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
16.45 % |
Mergers, acquisitions and licensing to continue drive industry growth
|
October 2006 |
£895 |
15.75 % |
F. Hoffmann-La Roche Ltd. Medical Equipment Company Share Analysis
|
September 2008 |
£370 |
15.75 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2001 |
£2195 |
15.05 % |
United States Diabetes Care Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Glucose Monitoring and Insulin Delivery Devices, Equipment and Supplies
|
April 2008 |
£990 |
14.35 % |
Commercializing Molecular Diagnostics:
Products, Services, Companies and Global Market
|
July 2008 |
£1690 |
14 % |
M&A trends in Pharma
|
October 2008 |
£6000 |
13.65 % |
Dr Reddy's Laboratories Generics Company Intelligence Report
|
June 2008 |
£195 |
13.5 % |
Biomarkers in Clinical Development
Implications for Personalized Medicine and Streamlining R&D
|
March 2005 |
£1950 |
13.5 % |
Dr Reddy's Laboratories Generics Company Intelligence Report
|
June 2008 |
£195 |
13.5 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
13.3 % |
Beyond the Blockbuster Drug
Strategies for nichebuster drugs, targeted therapies and personalized medicine.
|
February 2005 |
£1495 |
13.3 % |
Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012
|
June 2008 |
£990 |
12.6 % |
Canada Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012
|
June 2008 |
£990 |
12.6 % |
Biomarkers & Related Tests for Molecular Diagnostics & Pharma/ Biotech R&D
Companies, Products & Worldwide Market, 2004-2009
|
July 2005 |
£1235 |
12.5 % |
France Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012
|
June 2008 |
£990 |
12.25 % |
Analytical Tool: Competitive Outlook on HCV
|
July 2004 |
£1275 |
12 % |
Pharma R&D Fact Book, The
2006
|
November 2007 |
£595 |
12 % |
Global Pharmaceuticals - Yearly Update 2006
|
July 2007 |
£600 |
11.9 % |
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
|
August 2007 |
£7600 |
11.9 % |
SNP Genotyping and Analysis Markets
|
June 2008 |
£2605 |
11.55 % |
India In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
|
October 2008 |
£1955 |
11.55 % |
India Diabetes Care Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1060 |
11.2 % |
United States in Vitro Diagnostics Industry Report
Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Clinical Chemistry, Immunochemistry, Infectious Immunology, Microbiology, Genetic and Blood Test Reagents, Insturments and Test Kits
|
May 2008 |
£1955 |
11.2 % |
Switzerland Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
11 % |
Drug Repositioning Strategies
Innovative Strategies To Boost Pipeline Productivity
|
June 2007 |
£1495 |
11 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2935 |
10.85 % |
Canada Diabetes Care Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1060 |
10.15 % |
Cardiovascular Biomarkers: Players, products and prospects (Volume III)
|
August 2008 |
£595 |
10.15 % |
China In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012
|
October 2008 |
£1955 |
9.8 % |
Exiqon AS Product Pipeline Analysis
|
May 2008 |
£490 |
9.1 % |
Future Growth Opportunities in Generics
The impact of consolidation on market and competitive dynamics
|
November 2006 |
£1495 |
9.1 % |
United States Diabetes Care Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1060 |
9.1 % |
The Pharmaceutical Industry
Key events and trends shaping its current status and future direction
|
March 2006 |
£3690 |
8.75 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2935 |
8.75 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2935 |
8.75 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3400 |
8.5 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
8.4 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
8.4 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
8.4 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
8.4 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
8.4 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£3125 |
8.4 % |
Poland Pharmaceuticals and Healthcare Report Q3 2006
|
July 2006 |
£395 |
7.5 % |
Gene Expression Profiling Markets
|
January 2008 |
£2605 |
7.35 % |
Drug Delivery Technology
Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
7 % |
Global Market for Point of Care Diagnostics; The
|
December 2007 |
£695 |
7 % |
Drug Delivery Technology: Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
7 % |
The Pharmaceutical Industry 2008
Current and Future Trends and Strategic Issues Shaping Pharma
|
March 2008 |
£3010 |
7 % |
Cancer Biomarkers: Players, products and prospects (Volume I)
|
August 2008 |
£595 |
6.65 % |
Canada In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012
|
September 2008 |
£1095 |
6.65 % |
United Kingdom Diabetes Care Devices Investment Opportunities
Analysis and Forecasts to 2012
|
August 2008 |
£1045 |
6.3 % |
Bayer Schering Pharma Ag
PharmaVitae Profile
|
July 2008 |
£3010 |
6.3 % |
Personalized Medicine
|
August 2007 |
£1305 |
6.3 % |
Biomarkers: The Future of Next-Generation Drug R&D
|
September 2008 |
£1690 |
6.3 % |
Top 10 Medical Equipment Market Trends
|
May 2008 |
£2280 |
6.3 % |
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
|
August 2008 |
£1495 |
6.3 % |
The Pharmaceutical Market Outlook to 2015
Implementing innovative, long-term strategies for sustainable future growth
|
January 2005 |
£1495 |
6.3 % |
Estonia Pharmaceuticals and Healthcare Report Q3 2006
|
July 2006 |
£395 |
6 % |
Brazil Pharmaceuticals & Healthcare Report Q3 2006
|
July 2006 |
£395 |
6 % |
United States Pharmaceuticals and Healthcare Report Q3 2006
|
July 2006 |
£395 |
6 % |
The US Bio-Chip Market for Pharmaceutical Drug Discovery
Technology, Strategic Alliance, Patent Dispute and Market Update - 2002
|
May 2001 |
£715 |
5.6 % |
Angiogenesis Modulators
|
January 2008 |
£1825 |
5.25 % |
Pfizer
Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£1499 |
5.25 % |
From blockbuster to nichebuster
Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
|
July 2006 |
£1055 |
5.25 % |
DNA Sequencing Equipment and Services Markets
|
June 2007 |
£2280 |
5.25 % |
All Change in the US Pharma Market?
|
June 2008 |
£995 |
4.9 % |
Urinary Tract Agents Report 2005
|
April 2005 |
£1499 |
4.9 % |
RNA Interference Markets
|
September 2008 |
£1305 |
4.9 % |
United States In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012
|
September 2008 |
£1095 |
4.55 % |
Blood Glucose Testing and Diabetes Management
|
July 2007 |
£2215 |
4.55 % |
World Generic Market Report 2007
|
November 2006 |
£595 |
4.55 % |
Biosimilars: a viable market?
|
September 2008 |
£1295 |
4.2 % |
Immunogenicity to Biologics
Implications Of Reactions Against Biotech Drugs
|
November 2007 |
£1450 |
4.2 % |
Apoptosis
|
January 2008 |
£1890 |
4.2 % |
Global Biotech Report 2006, The
The rise of the Biotech blockbusters
|
September 2006 |
£4999 |
4.2 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£275 |
3.85 % |
World Biotech Market 2005, The
|
June 2005 |
£4999 |
3.85 % |
Anti-Obesity Treatments 2007-2012 - A blockbuster target market
|
July 2007 |
£1799 |
3.85 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
3.85 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£275 |
3.85 % |
Beckman Coulter, Inc. Medical Equipment Company Share Analysis
|
October 2008 |
£380 |
3.5 % |
Blood Banking and Blood products
|
March 2008 |
£2575 |
3.5 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
2.8 % |
Clinical Laboratory Testing Volume 1: Reagents and Instruments
|
March 2007 |
£2215 |
2.45 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
2.1 % |
|
|
|
|
